Suggested remit To appraise the clinical and cost effectiveness of selpercatinib within its marketing authorisation for treating advanced RET fusion-positive thyroid cancer and advanced RET mutation-positive medullary thyroid cancer (MTC).
Status In progress
Process STA 2018
ID number 3744

Project Team

Project lead Gavin Kenny

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Eli Lilly (selpercatinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Butterfly Thyroid Cancer Trust
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  Society for Endocrinology
  Thyroid Cancer Forum-UK


Comparator companies Bayer (sorafenib)
  Eisai (lenvatinib)
  Ipsen (cabozantinib) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
03 August 2020 Invitation to participate
15 May 2020 - 15 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance